Pablo Aschner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5678991/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multifaceted Determinants for Achieving Glycemic Control. Diabetes Care, 2009, 32, 227-233.	8.6	248
2	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diabetes and Vascular Disease Research, 2017, 14, 172-183.	2.0	102
3	Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet, The, 2012, 379, 2262-2269.	13.7	100
4	Determination of the cutoff point for waist circumference that establishes the presence of abdominal obesity in Latin American men and women. Diabetes Research and Clinical Practice, 2011, 93, 243-247.	2.8	95
5	Effects of Performing Morning Versus Afternoon Exercise on Glycemic Control and Hypoglycemia Frequency in Type 1 Diabetes Patients on Sensor-Augmented Insulin Pump Therapy. Journal of Diabetes Science and Technology, 2015, 9, 619-624.	2.2	94
6	Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12Âyears of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia, 2020, 63, 711-721.	6.3	76
7	Diabetes in South and Central America: An update. Diabetes Research and Clinical Practice, 2014, 103, 238-243.	2.8	73
8	Continuous Glucose Monitoring Versus Capillary Point-of-Care Testing for Inpatient Glycemic Control in Type 2 Diabetes Patients Hospitalized in the General Ward and Treated With a Basal Bolus Insulin Regimen. Journal of Diabetes Science and Technology, 2016, 10, 325-329.	2.2	61
9	Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care, 2017, 40, 164-170.	8.6	49
10	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. American Heart Journal, 2020, 219, 47-57.	2.7	45
11	Insulin glargine compared with premixed insulin for management of insulin-naÃ ⁻ ve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study. Journal of Diabetes and Its Complications, 2015, 29, 838-845.	2.3	34
12	Insulin Therapy in Type 2 Diabetes. American Journal of Therapeutics, 2020, 27, e79-e90.	0.9	26
13	Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1427-1434.	4.4	23
14	Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with TypeÂ2 Diabetes: Propensity Score Matched Analysis. Diabetes Therapy, 2020, 11, 305-318.	2.5	18
15	Transculturalizing Diabetes Prevention in Latin America. Annals of Global Health, 2018, 83, 432.	2.0	16
16	High Prevalence of Depressive Symptoms in Patients With Type 1 and Type 2 Diabetes in Developing Countries: Results From the International Diabetes Management Practices Study. Diabetes Care, 2021, 44, 1100-1107.	8.6	14
17	Glycemic control metrics using flash glucose monitoring and hospital complications in patients with COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 499-503.	3.6	13
18	Self-monitoring of blood glucose (SMBG) and glycaemic control in Cameroon: Results of the International Diabetes Management Practices Study (IDMPS). Diabetes Research and Clinical Practice, 2017, 126, 198-201.	2.8	12

PABLO ASCHNER

#	Article	IF	CITATIONS
19	One in Seven Insulin-Treated Patients in Developing Countries Reported Poor Persistence with Insulin Therapy: Real World Evidence from the Cross-Sectional International Diabetes Management Practices Study (IDMPS). Advances in Therapy, 2021, 38, 3281-3298.	2.9	11
20	Diabetes education and health insurance: How they affect the quality of care provided to people with type 1 diabetes in Latin America. Data from the International Diabetes Mellitus Practices Study (IDMPS). Diabetes Research and Clinical Practice, 2019, 147, 47-54.	2.8	10
21	External validation of the Finnish diabetes risk score in Venezuela using a national sample: The EVESCAM. Primary Care Diabetes, 2019, 13, 574-582.	1.8	8
22	Screening, prevalence, treatment and control of kidney disease in patients with type 1 and type 2 diabetes in low-to-middle-income countries (2005–2017): the International Diabetes Management Practices Study (IDMPS). Diabetologia, 2021, 64, 1246-1255.	6.3	6
23	Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: The EASIE post-hoc analysis and extension trial. Journal of Diabetes and Its Complications, 2015, 29, 134-141.	2.3	5
24	Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion. Diabetes Therapy, 2021, 12, 1491-1501.	2.5	5
25	Reasons for Discontinuation of Insulin Therapy—Results from the International Diabetes Management Practices Study (IDMPS). Diabetes, 2018, 67, 1026-P.	0.6	3
26	GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients. Current Hypertension Reviews, 2021, 17, 149-158.	0.9	2
27	Frequency of Diabetes-Related Complications in Type 1 and Type 2 Diabetes—Results from the International Diabetes Management Practices Study (IDMPS). Diabetes, 2018, 67, .	0.6	1
28	Cambios en la incidencia de diabetes mellitus tipo 1 en menores de 15 años en la ciudad de Bogotá, Colombia. Endocrinologia, Diabetes Y NutriciÓn, 2020, 67, 289-291.	0.3	1
29	Comparative efficacy and safety of basal insulins: A review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102318.	3.6	Ο